| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Opus Genetics, Inc. | Head of Fin. Quality Assurance | Common Stock | 193,128 | $388,187 | $2.01 | 22 Jan 2026 | Direct |
| Opus Genetics, Inc. | Head of Fin. Quality Assurance | Employee Stock Option (right to buy) | 39,500 | 13 Mar 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| IRD | Opus Genetics, Inc. | 22 Jan 2026 | 1 | $0 | 4 | Head of Fin. Quality Assurance | 26 Jan 2026, 19:49 |
| IRD | Opus Genetics, Inc. | 18 Jan 2026 | 1 | -$7,119 | 4 | Head of Fin. Quality Assurance | 21 Jan 2026, 16:05 |
| IRD | Opus Genetics, Inc. | 10 Jan 2026 | 1 | -$7,624 | 4 | Head of Fin. Quality Assurance | 13 Jan 2026, 17:21 |
| IRD | Opus Genetics, Inc. | 13 Mar 2025 | 2 | $0 | 4 | SVP of Finance | 17 Mar 2025, 20:54 |
| IRD | Opus Genetics, Inc. | 04 Feb 2025 | 1 | -$9,337 | 4 | SVP of Finance | 06 Feb 2025, 16:37 |
| IRD | Ocuphire Pharma, Inc. | 18 Jan 2024 | 2 | $0 | 4 | SVP of Finance | 22 Jan 2024, 18:01 |
| IRD | Ocuphire Pharma, Inc. | 10 Jan 2024 | 1 | -$12,897 | 4 | SVP of Finance | 12 Jan 2024, 16:17 |
| IRD | Ocuphire Pharma, Inc. | 10 Jan 2023 | 2 | $0 | 4 | SVP of Finance | 12 Jan 2023, 16:30 |
| IRD | Ocuphire Pharma, Inc. | 28 Jan 2022 | 1 | $0 | 4 | VP of Finance | 01 Feb 2022, 15:23 |